Startseite
Impressum
Datenschutz
 
arznei-telegramm 2006; 37: 52

 


Diplopia due to oseltamivir (TAMIFLU)? A 22-year old man was treated with the neuraminidase inhibitor oseltamivir (TAMIFLU) because of influenza. On day 4, oculomotor-paralysis with diplopia occurred, which resolved slowly after the medication was stopped (NETZWERK report no. 14.064). In another report of diplopia with oseltamivir the visual disorder in a woman lasted for several hours each time after taking the drug (no. 12.739). In Japan, the main market for the neuraminidase inhibitor, the summary of product characteristics (SPC) for TAMIFLU lists diplopia, alterations in the visual field, ocular pain and blurred vision as potential side effects (http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4180b_06_01_Tamiflu%20AE_reviewed.pdf). There are no corresponding warnings in the German SPC (Roche: TAMIFLU SPC, Jan. 2006).



© arznei-telegramm 5/06